MARKET

PABAF

PABAF

Patrys Ltd Melbourne
OTCPK
0.060
NaN%
Opening 09:30 07/01 EDT
OPEN
--
PREV CLOSE
0.060
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.060
52 WEEK LOW
0.050
MARKET CAP
40.00M
P/E (TTM)
-4.6512
1D
5D
1M
3M
1Y
5Y
1D
No Data
About PABAF
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.

Webull offers Patrys Ltd stock information, including OTCPK: PABAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PABAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PABAF stock methods without spending real money on the virtual paper trading platform.